Although most publications report that these mutations are mutually exclusive [14]–[19], evidence suggests [20] that a tumor can simultaneously harbor an activating EGFR mutation and mutations downstream in the pathway in the KRAS gene, which means that upstream inhibition of EGFR will have no therapeutic effect in these cases. This evidence concerns the gene EGFR and neoplasm.